Consent requirements for pelvic examinations
- Margaret L. Morris, MD, President
|You can read the latest one at http://www.controlled-trials.com/news/newsletter Sign up to receive these updates by sending a blank email to firstname.lastname@example.org|
METHODS: A consecutive series of adnexal cancers in BRCA1/2 mutation carriers diagnosed in 1980 to 2010 at the University Medical Center Groningen was analyzed.
RESULTS: We evaluated 55 BRCA1- and 16 BRCA2-related adnexal cancers, consisting of 51 ovarian, 13 tubal, and 7 peritoneal cancers. Peritoneal cancer was restricted to BRCA1 carriers. Ovarian and tubal cancer was equally present in both carrier groups. Median age at diagnosis was younger in BRCA1 compared with BRCA2 carriers (50 vs 54 years; P = 0.03). No other clinicopathologic differences were found. Regarding survival, a nonsignificant trend was noted for BRCA2 carriers to have fewer relapses, a longer time to first relapse, and a longer disease-free and overall survival.
CONCLUSIONS: Except for age at diagnosis and prevalence of peritoneal cancer, no significant clinicopathologic differences were found between BRCA1- versus BRCA2-associated adnexal cancer. On survival, it might be suggested that BRCA2 carriers have a more favorable outcome than BRCA1 carriers, marked by fewer relapses, a longer time to first relapse, and a longer disease-free and overall survival.
• Pressure, discomfort or pain in the pelvis, abdomen, back, or legs
• Gas, bloating, indigestion or abdominal distension
• Early satiety or feeling full even if you haven't eaten much
• Nausea, vomiting, loss of appetite or weight loss
• A change in the pattern of urination
• Abnormal vaginal bleeding, including abnormal menstrual periods